Skip to main contentAI and Advanced
/
GLENMARK · NSEBSE SENSEX74,400.89+0.09%BSE |
NIFTY 5023,286.8+0.30%NSE |
NIFTY BANK56,101.35-0.34%NSE |
NIFTY IT29,190.5+0.35%NSE |
NIFTY AUTO27,262.15+1.37%NSE |
NIFTY FMCG45,652.35+0.20%NSE |
NIFTY PHARMA26,515.95+1.41%NSE |
NIFTY 50022,662.55+0.58%NSE |
GL
NSE · Equity shares · Biotechnology & Drugs-6.50 · -0.27%
Glenmark Pharmaceuticals GLENMARK
NSE:INR 2,403.5
BSE:INR 2,403.05
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for GLENMARK
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,410
Day rangeINR 2,306.3 — INR 2,425.8
52-week rangeINR 1,792.6 — INR 2,537.6
Volume6.77 L
Market cap64,877.96
P/E45.68
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)16,982.51
Net Income (INR Cr)1,361.85
Rev Growth (5 Year %)9.19
EPS Growth (5 Year %)7.01
P/E Ratio45.68
EPS103.32
Research path: Interpret Glenmark Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
GLENMARKGlenmark Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 19,907.88 | 16,049.55 | 14,358.62 |
| Other Liabilities Total | 2,532.12 | 475.96 | 540.52 |
| Long Term Debt | 0 | 512.7 | 0 |
| Common Stock Total | 28.22 | 28.22 | 28.22 |
| Other Current Assets Total | 1,506.14 | 52.25 | 23.26 |
| Total Assets | 19,907.88 | 16,049.55 | 14,358.62 |
| Current Portof LT Debt/Capital Leases | 107.22 | 92.26 | 245.88 |
| Cash | 1,174.71 | 1,675.71 | 1,658.27 |
| Total Equity | 10,512.11 | 8,849.44 | 7,847.93 |
| Long Term Investments | 109.88 | 56.36 | 789.66 |
| Retained Earnings(Accumulated Deficit) | 10,483.89 | 8,990.15 | 8,060.97 |
| Total Common Shares Outstanding | 28.22 | 28.22 | 28.22 |
| Tangible Book Valueper Share Common Eq | 283.7 | 261.85 | 230.82 |
| Goodwill Net | 82.86 | 70.27 | 67.36 |
| Total Liabilities | 9,395.77 | 7,200.11 | 6,510.7 |
| Total Debt | 593.53 | 2,472.67 | 1,230.93 |
| Short Term Investments | 224.73 | Not available | Not available |
| Cashand Short Term Investments | 1,399.44 | 1,675.71 | 1,658.27 |
| Total Receivables Net | 4,963.35 | 4,181.06 | 2,999.01 |
| Notes Payable/Short Term Debt | 0 | 1,681.5 | 833.36 |
| Deferred Income Tax | 1.23 | 58.59 | 0.28 |
| Accounts Receivable-Trade Net | 4,963.35 | 3,341.95 | 1,858.41 |
| Property/Plant/Equipment Total-Net | 4,317.44 | 3,861.35 | 3,537.48 |
| Minority Interest | -0.32 | -0.37 | -0.38 |
| Total Current Liabilities | 6,376.43 | 5,967.02 | 5,818.59 |
| Total Inventory | 3,430.78 | 3,281.2 | 2,720.85 |
| Accounts Payable | 3,743.87 | 2,595.69 | 2,607.73 |
| Other Currentliabilities Total | 2,525.33 | 673.32 | 1,041 |
| Total Long Term Debt | 486.31 | 698.91 | 151.69 |
| Intangibles Net | 2,423.36 | 1,390.03 | 1,267.21 |
| Other Long Term Assets Total | 1,443.48 | 1,202.14 | 1,120.88 |
| Note Receivable-Long Term | 231.13 | 173.94 | 147.95 |
| Total Current Assets | 11,299.71 | 9,295.47 | 7,428.08 |
| Capital Lease Obligations | 486.31 | 186.21 | 151.69 |
| Accumulated Depreciation Total | Not available | -2,793.48 | -2,492.4 |
| Accrued Expenses | Not available | 924.25 | 1,090.62 |
| Other Equity Total | Not available | -1,855.49 | -1,927.82 |
| Prepaid Expenses | Not available | 105.25 | 26.69 |
| Additional Paid-In Capital | Not available | 1,686.56 | 1,686.56 |
| Property/Plant/Equipment Total-Gross | Not available | 6,112.84 | 5,610.55 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio6.68
Price to Sale Ratio3.82
Growth
Debt 5Yr CAGR %-34.67
Margins
Operating Margin 12m10.56
Operating Margin 5y Avg7.3
Net Profit Margin 12m9.24
Net Profit Margin 5y2.25
Yield
Dividend Yield %0.22
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk30.95
Analyst consensus
ConsensusStrong Buy
Consensus score1.78
Analyst opinions9
Strong Sell count0
Sell count0
Hold count2
Buy count3
Strong Buy count4
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 46.65%
- FII
- 20.89%
- MF
- 16.76%
- Other
- 15.70%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Glenmark Consolidated March 2026 Net Sales at Rs 3,770.59 crore, up 15.8% Y-o-Y - Moneycontrol.comMarket news · 3 Jun 2026, 12:44 pm
Glenmark Consolidated March 2026 Net Sales at Rs 3,770.59 crore, up 15.8% Y-o-Y Moneycontrol.com
Number of shareholders of Glenmark Pharmaceuticals Limited – NSE:GLENMARK - TradingViewMarket news · 3 Jun 2026, 8:43 am
Number of shareholders of Glenmark Pharmaceuticals Limited – NSE:GLENMARK TradingView
Glenmark Pharmaceuticals Ltd. is Rated Strong Buy - Markets MojoMarket news · 3 Jun 2026, 2:18 am
Glenmark Pharmaceuticals Ltd. is Rated Strong Buy Markets Mojo
Glenmark Pharmaceuticals Q4 FY26: Exceptional Quarter Marred by Sequential Decline - Markets MojoMarket news · 2 Jun 2026, 7:45 pm
Glenmark Pharmaceuticals Q4 FY26: Exceptional Quarter Marred by Sequential Decline Markets Mojo
Glenmark Pharmaceuticals appoints Ajay Jajoo as Group VP & Global Corporate Controller - Exchange4MediaMarket news · 2 Jun 2026, 2:19 pm
Glenmark Pharmaceuticals appoints Ajay Jajoo as Group VP & Global Corporate Controller Exchange4Media
Glenmark Pharma targets ₹18,000 crore revenue by FY27 on broad-based global growth - CNBC TV18Market news · 2 Jun 2026, 12:21 pm
Glenmark Pharma targets ₹18,000 crore revenue by FY27 on broad-based global growth CNBC TV18
Corporate actions
Events
- dividendRs.2.5000 per share(250%)Final Dividend
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- dividendRs.2.5000 per share(250%)Interim Dividend
- board MeetingsInterim Dividend
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Glenmark Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- GLENMARK
- BSE Code
- 532296
Questions
Stock FAQ
What is the symbol and ISIN of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has the symbol GLENMARK and ISIN - INE935A01035.
What is the current price of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals is currently trading at INR 2,403.50.
What are the year high and year low of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a year high of INR 2,537.60 and a year low of INR 1,792.60.
What is the market capitalization of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a market capitalization of INR 64,877.96 crore.
What is the P/E ratio of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a P/E ratio of 45.68.
What is the dividend yield of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a dividend yield of 0.22%.
How is the financial performance of Glenmark Pharmaceuticals based on revenue, net income, and EPS?
Glenmark Pharmaceuticals has revenue of INR 16,982.51 crore, net income of INR 1,361.85 crore, and EPS of INR 96.01.
What is the book value of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a book value of NA.
What is the debt-to-equity ratio of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals has a price-to-book ratio of NA and a price-to-sales ratio of 3.82.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.